Biogen Idec up for sale
Executive Summary
Biogen Idec hires Goldman Sachs and Merrill Lynch to evaluate third party interest, including activist investor Carl Icahn, in acquiring the biotechnology firm, according to an Oct. 12 announcement. Biogen has a market capitalization of about $20 bil. and sports a portfolio that includes multiple sclerosis products Avonex (interferon beta-1a) and Tysabri (natalizumab), as well as the non-Hodgkin's lymphoma treatment Rituxan (rituximab), which it co-markets with Genentech...